Sulfonylureas inhibit cytokine-induced eosinophil survival and activation

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5546-5553

  Bankers Fulbright, Jennifer L ^a   Kephart, Gail M ^a   Loegering, David A ^a   Bradford, Annabel L ^a   Okada, Shinji ^a   Kita, Hirohito ^a   Gleich, Gerald J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROMAKALIM; CYTOKINE; DEXAMETHASONE; DIAZOXIDE; DRUG RECEPTOR; GLIBENCLAMIDE; GLIPIZIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; MESSENGER RNA; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; RECOMBINANT INTERLEUKIN 5; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ALLERGY; ARTICLE; ASTHMA; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG MECHANISM; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CELL SEPARATION; CELL SURVIVAL; CROMAKALIM; CYTOKINES; DEXAMETHASONE; DRUG SYNERGISM; EOSINOPHILS; GLYBURIDE; GROWTH INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIDOCAINE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; SULFONYLUREA COMPOUNDS; SUPEROXIDES; TETRAETHYLAMMONIUM;

EID: 0032101945     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Seminario, M. C., and G. J. Gleich. 1994. The role of eosinophils in the pathogenesis of asthma. Curr. Opin. Immunol. 6:860.
2. Thomas, L. H., and J. A. Warner. 1996. The eosinophil and its role in asthma. Gen. Pharmacol. 27:593.
3. Barnes, P. J. 1993. Anti-inflammatory therapy for asthma. Annu. Rev. Med. 44:229.
4. Greenberger, P. A. 1992. Corticosteroids in asthma: rationale, use, and problems. Chest 101:4185.
5. Szefler, S. J., A. K. Kamada, D. Hughes, A. M. Brenner, and E. W. Gelfand. 1992. Alternative treatments for asthma: assessing the need. J. Asthma 29:91.
6. Hunt, L. W., H. A. Swedlund, and G. J. Gleich. 1996. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin. Proc. 71:361.
7. Stern, M., L. Meagher, J. Savill, and C. Haslett. 1992. Apoptosis in human eosinophils: programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J. Immunol. 148:3543.
8. Owen, W. F., Jr., M. E. Rothenberg, D. S. Silberstein, J. C. Gasson, R. L. Stevens, K. F. Austen, and R. J. Soberman. 1987. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J. Exp. Med. 166:129.
9. Rothenberg, M. E., W. F. Owen Jr., D. S. Silberstein, J. Woods, R. J. Soberman, K. F. Austen, and R. L. Stevens. 1988. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3, J. Clin. Invest. 81:1986.
10. Tsuyuki, S., C. Bertrad, F. Erard, A. Trifilieff, J. Tsuyuki, M. Wesp, G. P. Anderson, and A. J. Coyle. 1995. Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J. Clin. Invest. 96:2924.
11. Wooley, K. L., P. G. Gibson, K. Carty, A. J. Wilson, S. H. Twaddell, and M. J. Woolley. 1996. Eosinophil apoptosis and the resolution of airway inflafflmation in asthma. Am. J. Respir. Crit. Care Med. 154:237.
12. Sur, S., G. J. Gleich, M. C. Swanson, K. R. Bartemes, and D. H. Brodie. 1995. Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. J. Allergy Clin. Immunol. 96:661.
13. Kita, H., D. A. Weiler, R. Abu-Ghazaleh, C. J. Sanderson, and G. J. Gleich. 1992. Release of granule proteins from eosinophils cultured with IL-5. J. Immunol. 149:629.
14. Ohnishi, T., H. Kita, A. N. Mayeno, S. Okada, S. Sure, D. H. Brodie, and G. J. Gleich. 1996. Lidocaine in the bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clin. Exp. Immunol. 104:325.
15. Adachi, T., S. Motojima, A. Hirata, T. Fukuda, N. Kihara, A. Kosaku, H. Ohtake, and S. Makino. 1996. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J. Allergy Clin. Immunol. 98:5207.
16. Wallen, N., H. Kita, D. Weiler, and G. J. Gleich. 1991. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J. Immunol. 147:3490.
17. Okada, S., J. B. Hagan, M. Kato, J. L. Bankers-Fulbright, L. W. Hunt, G. J. Gleich, and H. Kita. 1998. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J. Immunol. 160:4010.
18. Strichartz, G. R., ed. 1987. Local Anesthetics. Springer-Verlag, Berlin.
19. 2+. Am. J. Physiol. 263:C674.
20. Olschewski, A., M. E. Brau, H. Olschewski, G. Hempelmann, and W. Vogel. 1996. ATP-dependem potassium channel in rat cardiomyocytes is blocked by lidocaine. Circulation 93:646.
21. + channels in Xenopus oocytes. Eur. J. Pharmacol. 247:267.
22. Ide, M., D. Weiler, H. Kita, and G. J. Gleich. 1994. Ammonium chloride exposure inhibits cytokine-mediated eosinophil survival. J. Immunol. Methods 168:187.
23. Horie, S., G. J. Gleich, and H. Kita. 1996. Cytokines directly induce degranulation and Superoxide production from human eosinophils. J. Allergy Clin. Immunol. 98:371.
24. Dive, C., C. D. Gregory, D. J. Phipps, D. L. Evans, A. E. Milner, and A. H. Wyllie. 1992. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim. Biophys. Acta 1133:275.
25. Sun, X. M., R. T. Snowden, D. N. Skilleter, D. Dinsdale, M. G. Ormerud, and G. M. Cohen. 1992. A flow-cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Anal. Biochem. 204:351.
26. Aguilar-Bryan, L., D. A. Nelson, Q. A. Vu, M. B. Humphrey, and A. E. Boyd III. 1990. Photoaffinity labeling and partial purification of the β cell sulfonylurea receptor using a novel, biologically active glyburide analog. J. Biol. Chem. 265:8218.
27. Aguilar-Bryan, L., C. G. Nichols, S. W. Wechsler, J. P. Clement IV. A. E. Boyd III, G. Gonzalez, H. Herrera-Sosa, K. Nguy, J. Bryan, and D. A. Nelson. 1995. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268:423.
28. Sturgess, N. C., M. L. Ashford, D. L. Cook, and C. N. Hales. 1985. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 8453:474.
29. Gallin, E. K., and S. Grinstein. 1992. Ion channels and carriers in leukocytes: distribution and functional role. In Inflammation: Basic Principles and Clinical Correlates, 2nd Ed. J. I. Gallin, I. M. Goldstein, and R. Snyderman, eds. Raven Press, New York, pp. 441-458.
30. Panten, U., M. Schwanstecher, and C. Schwanstecher. 1996. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol. 104:1.
31. KATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270:1166.
32. + channels. Neuron 16:1011.
33. Santerre, R. F., R. A. Cook, R. M. D. Crisel, J. D. Sharp, R. J. Schmidt, D. C. Williams, and C. P. Wilson. 1981. Insulin synthesis in a clonal line of simian virus 40-transformed hamster pancreatic beta cells. Proc. Natl. Acad. Sci. USA 78:4339.
34. Savill, J., and C. Haslett. 1995. Granulocyte clearance by apoptosis in the resolution of inflammation. Semin. Cell. Biol. 6:385.
35. Shi, H., S. Quin, G. Huang, Y. Chen, C. Xiao, H. Xu, G. Giang, Z. Xie, X. Qin, J. Wu, G. Li, and C. Zhang. 1997. Infiltration of eosinophils into the asthmatic airways caused by interleukin-5. Am. J. Respir. Cell Mol. Biol. 16:220.
36. Ohnishi, T., H. Kita, D. Weiler, S. Sur, J. B. Sedgwick, W. J. Calhoun, W. W. Busse, J. S. Abrams, and G. J. Gleich. 1993. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am. Rev. Respir. Dis. 147:901.
37. Barnes, P. J. 1995. Anti-inflammatory mechanisms of glucocorticoids. Biochem. Soc. Trans. 23:940.
38. Pretolani, M., and B. B. Vargaftig. 1996. Role of eosinophil mobilization and activation in experimental airway inflammation and bronchopulmonary hyperreactivity. Ann. NY Acad. Sci. 796:72.
39. Pretolani, M., C. Ruffie, D. Joseph, M. G. Campos, M. K. Church, J. Lefort, and B. B. Vargaftig. 1994. Role of eosinophil activation in the bronchial reactivity of allergic guinea pigs. Am. J. Respir. Crit. Care Med. 149:1167.
40. Kouro, T., Y. Kikuchi, H. Kanazawa, K. Hirokawa, N. Harada, M. Shiiba, H. Wakao, S. Takaki, and K. Takatsu. 1996. Critical proline residues of the cytoplasmic domain of the IL-5 receptor a chain and its function in IL-5 mediated activation of JAK kinase and STAT5. Int. Immunol. 8:237.
41. Ding, D. X.-H., C. J. Rivas, M. L. Heaney, M. A. Raines, J. C. Vera, and D. W. Golde. 1994. The α subunit of the human granulocyte-macrophage colonystimulating factor receptor signals for glucose transport via a phosphorylation-independent pathway. Proc. Natl. Acad. Sci. USA 91:2537.
42. Takaki, S., H. Kanazawa, M. Shiiba, and K. Takatsu. 1994. A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor α chain and its function on IL-5-mediated growth signal transduction. Mol. Cell. Biol. 14:7404.
43. Weiss, M., C. Yokoyama, Y. Shikama, C. Naugle, B. Druker, and C. A. Sieff. 1993. Human granulocyte-macrophage colony-stimulating factor receptor signal transduction requires the proximal cytoplasmic domains of the α and β subunits. Blood 82:3298.
44. Polotskaya, A., Y. Zhao, M. L. Lilly, and A. S. Kraft. 1993. A critical role for the cytoplasmic domain of the granulocyte-macrophage colony-stimulating factor α receptor in mediating cell growth. Cell Growth Differ. 4:523.
45. McKinnon, M., K. Page, I. J. Uings, M. Banks, D. Fattah, A. E. I. Proudfoot, P. Graber, C. Arod, R. Fish, T. N. C. Wells, and R. Solan. 1997. An interieukin-5 mutant distinguishes between two functional responses in human eosinophils. J. Exp. Med. 186:121.
46. Blattner, F. R., G. Plunkett, C. A. Bloch, N. T. Perna, V. Burland, M. Riley, J. Colladovides, J. D. Glasner, C. K. Rode, G. F. Mayhew, J. Gregor, N. W. Davis, H. A. Kirkpatrick, M. A. Goeden, D. J. Rose, B. Mau, and Y. Shao. 1997. The complete genome sequence of Escherichia coli K-12. Science 277:1453.
47. Small, R. C., J. L. Berry, J. F. Burka, S. J. Cook, R. W. Foster, K. A. Green, and M. A. Murray. 1992. Potassium channel activators and bronchial asthma. Clin. Exp. Allergy 22:11.
48. Cook, N. S., and I. D. Chapman. 1993. Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma. Cardiovasc. Drugs Ther. 7:555.
49. Williams, A. J., T. H. Lee, G. M. Cochrane, A. Hopkirk, T. Vyse, F. Chiew, E. Lavender, D. H. Richards, S. Owen, P. Stone, S. Church, and A. A. Woodcock. 1990. Attenuation of nocturnal asthma by cromakalim. Lancet 336:334.
50. Kidney, J. C., R. W. Fuller, Y. M. Worsdell, E. A. Lavender, K. F. Chung, and P. J. Barnes. 1993. Effect of an oral potassium channel activator, BRL 38227, on airway function and responsiveness in asthmatic patients: comparison with oral salbutamol. Thorax 48:130.
51. + channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J. Gen. Physiol. 100:573.